Identification and Characterization of Human Wee1B, a New Member of the Wee1 Family of Cdk-inhibitory Kinases
Overview
Molecular Biology
Affiliations
Background: In eukaryotic cells, the kinase activity of the mitosis-promoting complex composed of cyclin B and Cdc2 (Cdk1) is negatively regulated by the phosphorylation of Cdk1 on threonine or tyrosine residues within its ATP binding domain.
Results: We identified human Wee1B by searching a sequence database. The predicted human Wee1B protein comprises 561 amino acids. Northern blot analysis revealed that human Wee1B mRNA is particularly abundant in testis. Interestingly, RT-PCR using early embryos revealed that the Wee1B product was readily detectable at the mature oocyte, but abruptly disappeared at embryonic day 2.5, suggesting that the amount of Wee1B mRNA is dependent on the maternal expression. GFP-Wee1B showed a predominantly nuclear localization in HeLa cells. Human Wee1B was able to rescue the lethal phenotype of the fission yeast wee1-50Deltamik1 mutant, and over-expression of the human protein in these cells resulted in cell elongation as a result of arrest of the cell cycle at the G2-M transition. Recombinant Wee1B effectively phosphorylated cyclin B-associated Cdk1 on tyrosine-15, resulting in an inactivation of the kinase activity of Cdk1.
Conclusion: We identified human Wee1B as a novel Cdk1-inhibitory kinase. The identification of this new member of the Wee1 family suggests that inhibition of Cdk1 is mediated at multiple levels in mammals.
Novel splicing mutations in PATL2 and WEE2 cause oocyte degradation and fertilization failure.
Liu Z, Zhu L, He H, Hou M, Jia W, Jin L J Assist Reprod Genet. 2024; 41(12):3337-3345.
PMID: 39476306 PMC: 11707231. DOI: 10.1007/s10815-024-03260-0.
Oocyte-specific Wee1-like protein kinase 2 is dispensable for fertility in mice.
Nozawa K, Liao Z, Satouh Y, Geng T, Ikawa M, Monsivais D PLoS One. 2023; 18(8):e0289083.
PMID: 37527245 PMC: 10393137. DOI: 10.1371/journal.pone.0289083.
Cyclers' kinases in cell division: from molecules to cancer therapy.
Milletti G, Colicchia V, Cecconi F Cell Death Differ. 2023; 30(9):2035-2052.
PMID: 37516809 PMC: 10482880. DOI: 10.1038/s41418-023-01196-z.
Synthetic and Medicinal Chemistry Approaches Toward WEE1 Kinase Inhibitors and Its Degraders.
Alli V, Yadav P, Suresh V, Jadav S ACS Omega. 2023; 8(23):20196-20233.
PMID: 37323408 PMC: 10268025. DOI: 10.1021/acsomega.3c01558.
DNA Damage Response in Cancer Therapy and Resistance: Challenges and Opportunities.
Jurkovicova D, Neophytou C, cipak Gasparovic A, Goncalves A Int J Mol Sci. 2022; 23(23).
PMID: 36499000 PMC: 9735783. DOI: 10.3390/ijms232314672.